Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
COVID-19
Cancer care
Continuity of care
Lung cancer
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
01
04
2021
revised:
07
06
2021
accepted:
09
07
2021
pubmed:
31
8
2021
medline:
24
9
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
Patients with lung cancer (LC) are susceptible to severe outcomes from COVID-19. This study evaluated disruption to care of patients with LC during the COVID-19 pandemic. The COVID-19 and Cancer Outcomes Study (CCOS) is a prospective cohort study comprised of patients with a current or past history of hematological or solid malignancies with outpatient visits between March 2 and March 6, 2020, at two academic cancer centers in the Northeastern United States (US). Data was collected for the three months prior to the index week (baseline period) and the following three months (pandemic period). 313 of 2365 patients had LC, 1578 had other solid tumors, and 474 had hematological malignancies. Patients with LC were not at increased risk of COVID-19 diagnosis compared to patients with other solid or hematological malignancies. When comparing data from the pandemic period to the baseline period, patients with LC were more likely to have a decrease in in-person visits compared to patients with other solid tumors (aOR 1.94; 95% CI, 1.46-2.58), but without an increase in telehealth visits (aOR 1.13; 95% CI 0.85-1.50). Patients with LC were more likely to experience pandemic-related treatment delays than patients with other solid tumors (aOR 1.80; 95% CI 1.13-2.80) and were more likely to experience imaging/diagnostic procedure delays than patients with other solid tumors (aOR 2.59; 95% CI, 1.46-4.47) and hematological malignancies (aOR 2.01; 95% CI, 1.02-3.93). Among patients on systemic therapy, patients with LC were also at increased risk for decreased in-person visits and increased treatment delays compared to those with other solid tumors. Patients with LC experienced increased cancer care disruption compared to patients with other malignancies during the early phase of the COVID-19 pandemic. Focused efforts to ensure continuity of care for this patient population are warranted.
Identifiants
pubmed: 34461400
pii: S0169-5002(21)00455-4
doi: 10.1016/j.lungcan.2021.07.002
pmc: PMC8284065
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-83Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
ESMO Open. 2020 Jun;5(Suppl 3):
pubmed: 32581069
Cancer Cell. 2020 Dec 14;38(6):769-770
pubmed: 33176161
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
JAMA Oncol. 2020 Dec 1;6(12):1881-1889
pubmed: 33119036
J Thorac Oncol. 2020 Jul;15(7):1119-1136
pubmed: 32422364
JAMA Oncol. 2021 Mar 1;7(3):458-460
pubmed: 33443549
JAMA Oncol. 2020 Nov 1;6(11):1805-1806
pubmed: 32940638
JCO Oncol Pract. 2020 Sep;16(9):579-586
pubmed: 32453656